secwatch.observer — SEC 8-K summary
======================================

Issuer:     Prime Medicine, Inc. (PRME)
CIK:        0001894562
Form:       8-K
Filed at:   2023-05-17T23:59:59+00:00
Accession:  0001628280-23-018552
Event type: other_material
Sentiment:  positive
Materiality: 0.65
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Prime Medicine presents preclinical data on CGD correction and PASSIGE CAR-T platform at ASGCT
--------------------------------------------------------------------------------

- Prime editing corrected CGD mutation in >90% of CD34+ cells from four donors with no off-target edits detected.
- Long-term engraftment >92% editing in vivo supports PM359 advancement as CGD treatment candidate.
- PASSIGE platform inserted CD19 CAR (3.5 kb) at TRAC locus in 60% of T cells, with >90% TCR loss.
- PASSIGE-generated CAR-T cells showed potent anti-tumor activity in vitro and in vivo.
- Multiplex prime editing achieved >90% B2M knockout in primary T cells, enabling allogeneic CAR-T potential.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1894562/000162828023018552/0001628280-23-018552-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1894562/000162828023018552/prme-20230517.htm
  HTML page:      https://secwatch.observer/filing/0001628280-23-018552

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer